C-Peptide as a Marker for Diabetic NephropathyMaimoona Mushtaq Masoom* and Fatma Albiladi
King Abdul Aziz University Hospital, Jeddah Saudi Arabia
- *Corresponding Author:
- Maimoona Mushtaq Masoom
King Abdul Aziz University Hospital
Jeddah, Saudi Arabia
E-mail: [email protected]
Received date: June 7, 2017; Accepted date: June 26, 2017; Published date: June 30, 2017
Citation: Masoom MM, Albiladi F (2017) C-Peptide as a Marker for Diabetic Nephropathy. Intern Med 7:245. doi:10.4172/2165-8048.1000245
Copyright: © 2017 Masoom MM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Diabetes mellitus is a metabolic disorder of multiple aetiology. Destruction of pancreatic beta cells, hyperglycaemia, and insulin deficiency cause type 1 diabetes mellitus. Diabetic nephropathy is the damage to kidneys because of diabetes. It is predominantly seen in patients with type 1 diabetes (insulin-dependent type) and type 2 diabetes (non-insulin-dependent type). An active peptide hormone, C-peptide has the likelihood of causing major physiological effects. C-peptide is the best indication of endogenous insulin secretion occurring in patients with diabetes. In this regard, the current study undertakes a comprehensive study of C-peptide and kidney (renal) failure in patients with diabetes mellitus in order to assess their association. A prospective cross sectional study is conducted at King Abdul Aziz University Hospital. The subjects for this study were patients with type 2 DM. Laboratory tests such as HbA1c, serum creatinine, urine albumin and creatinine, fasting serum C-peptide, and blood urea nitrogen are conducted. Data was analysed using analysis of variance (ANOVA) test to compare the values between different category patients. The study also found that there exists a significant mean difference between Cystacin C and C-peptide levels. However, the study has certain limitations. Firstly, the number of patients with elevated levels of serum C-peptide was very small, and hence, valid conclusions with respect to the association of serum C-peptide with renal parameters could not be discerned. Therefore, there is a need for further studies with more number of patients.